H19

Gene basic information

symbol H19
name H19, imprinted maternally expressed transcript (non-protein coding)
location 11p15.5
alias_symbol D11S813E|ASM|ASM1|NCRNA00008|LINC00008
alias_name non-protein coding RNA 8|long intergenic non-protein coding RNA 8
Tissuebladder,bone,bone marrow,breast,colorectum,esophagus,gallbladder,kidney,larynx,liver,lung,nasopharynx,nervous system,others,ovary,pancreas,prostate,stomach,thyroid,
Cancerbladder cancer,breast cancer,colorectal cancer,embryonic carcinoma,esophageal cancer,gallbladder cancer,gastric cancer,glioma,hepatic cancer,laryngeal squamous cell cancer,leukemia,lung cancer,nasopharyngeal cancer,non-small-cell lung cancer,osteosarcoma,ovarian cancer,pancreatic cancer,prostate cancer,renal cancer,thyroid cancer,


Description

LncRNA H19 is a precursor of miR-675-5p/miR-675-3p. It mainly acts as an oncogene in multiple cancers. It is higher in glioma (1), thyroid cancer (2), nasopharyngeal carcinoma (3), non-small-cell lung cancer (4), breast cancer (5), esophageal cancer (6), gastric cancer (7), gallbladder carcinoma (8), pancreatic cancer (9), colon cancer (10), bladder cancer (11), renal cell carcinoma (12), ovarian cancer (13), embryonic carcinoma (14), but has dual roles in hepatocellular carcinoma (15, 16). H19 expression level is associated with clinicopathological parameters such as tumor differentiation, TNM stage and prognosis etc. (17, 8, 7, 18, 15, 4, 12). Functionally, H19 regulates cancer cell proliferation, migration, metastasis, invasion, apoptosis and EMT. (19, 17, 6, 12, 2).
At molecular level, H19 can act as ceRNA via binding to miR-630 (3), miR-17-5p (2) and miR-141(20). Besides, it can also bind to eIF4A3 (21), ISM1 (7), c-myc (4) and let-7 (9). Mechanistically, H19 negatively regulates RB (10), P21 (21), Nkd1, (11), c-Cbl, Cbl-b, EGFR (5), E-cadherin (8), miR-107(22) and miR-141(23), and positively regulates cyclin A2, cyclin B1(24), cyclin D1, cyclin E1, CDK4 (21), ID2 (19), YES1 (2), YAP1 (17), EZH2 (3), miR-200s (15), ZEB1(20), β-catenin (11), Twist1, TGF-β1, IL-6 and Vimentin (8). By regulating these factors, H19 play roles in a variety of biological processes.
Besides, H19 affects chemotherapy and hormonotherapy response in multiple cancers (25, 26, 27). Moreover, polymorphism of H19 may contribute to carcinogenesis (28, 29).


Cancer related information

download as excel csv txt

LncRNA tissue cancer type expression level oncogene/suppress gene pathway binding gene/factor associated gene/factor proliferation apoptosis migration EMT invasion metastasis prognosis tag PMID
0 H19 bladder bladder cancer up / 11193051
1 H19 liver hepatic cancer up onco IGF2+ - 15736456
2 H19 breast breast cancer up onco +c-Myc + 16707459
3 H19 lung lung cancer up onco +c-Myc IGF2- + 16707459
4 H19 liver hepatic cancer up onco HIF1α pathway p57+,ANG+ hypoxia 17786216
5 H19 bladder bladder cancer / / SNP 18262338
6 H19 colorectum colorectal cancer up / RB- + 19926638
7 H19 bladder bladder cancer up / 21162716
8 H19 stomach gastric cancer up onco p53- + - 22776265
9 H19 liver hepatic cancer down TS N-cadherin-,Snail1-,vimentin-,Twist1-,miR-200s+ - - 23222811
10 H19 bladder bladder cancer up onco Nkd1- E-cad- β-catenin+ + 23354591
11 H19 bladder bladder cancer up onco ID2+ + 23399020
12 H19 stomach gastric cancer up / - 24063685
13 H19 stomach gastric cancer up onco RUNX1- + 24388988
14 H19 nervous system glioma up onco miR-675 + 24466011
15 H19 nervous system glioma up onco + - 27981546
16 H19 stomach gastric cancer up onco c-Myc+ + + - 24671855
17 H19 bone marrow leukemia up onco c-Myc + + chemotherapy resistance 24685695
18 H19 liver hepatic cancer up onco +E2F1 +AFB1 + + 24761865
19 H19 stomach gastric cancer up onco ISM1 + + + + 24810858
20 H19 pancreas pancreatic cancer up onco let-7 + + + 24920070
21 H19 liver hepatic cancer down / AKT/GSK-3β/Cdc25A AKT-,Cdc25A- - - 24939300
22 H19 prostate prostate cancer down TS TGFBI- 24988946
23 H19 ovary ovarian cancer up onco H1.3 + 25205099
24 H19 breast breast cancer up onco + hormonal resistance 25846769
25 H19 kidney renal cancer up onco + - + + - 25866221
26 H19 stomach gastric cancer / / SNP 25944697
27 H19 colorectum colorectal cancer up onco miR-138,miR-200a vimentin-,ZEB1-,ZEB2- + 26068968
28 H19 stomach gastric cancer up / 26096073
29 H19 stomach gastric cancer up onco miR-141- ZEB1+ + + 26160158
30 H19 bladder bladder cancer up onco +YAP1 + + 26163939
31 H19 esophagus esophageal cancer up onco + + + 26171017
32 H19 bladder bladder cancer / onco p53-,Bax-,Bcl-2+,cyclin D1+ + - 26198047
33 H19 liver hepatic cancer / / 26272696
34 H19 nervous system glioma up onco + cancer stem cells 26274999
35 H19 breast breast cancer up onco c-Cbl-,Cbl-b-,EGFR- + + 26353930
36 H19 liver hepatic cancer / / miR675 26376677
37 H19 others embryonic carcinoma up onco N-Cadherin+,E-Cadherin- + cancer stem cells 26415227
38 H19 lung non-small-cell lung cancer up onco c-Myc + - 26482621
39 H19 ovary ovarian cancer up onco cyclin A2+,cyclin B1+ + - 26617715
40 H19 nervous system glioma up onco + 26692922
41 H19 lung non-small-cell lung cancer up / c-Myc+ miR-107- 26722426
42 H19 lung lung cancer / / SNP,chemotherapy resistance 26729200
43 H19 stomach gastric cancer up onco E-cadherin- + + - 26774144
44 H19 larynx laryngeal squamous cell cancer up onco miR-148a-3p-,DNMT1- + + + - 26872375
45 H19 breast breast cancer / / SNP 26886624
46 H19 stomach gastric cancer up onco Akt/mTOR pathway RUNX1- + + 26931432
47 H19 stomach gastric cancer / / - 26935047
48 H19 nervous system glioma up onco CD133+,NANOG+,Oct4+,Sox2+ cancer stem cells 26983719
49 H19 colorectum colorectal cancer up onco eIF4A3 cyclin D1+,cyclin E1+,CDK4+,p21- + - 26989025
50 H19 colorectum colorectal cancer / / SNP 27027436
51 H19 nasopharynx nasopharyngeal cancer up onco miR-630 EZH2+ + 27040767
52 H19 gallbladder gallbladder cancer up onco Twist+,TGF-β1+,IL-6+,vimentin+,E-cadherin- + + 27073719
53 H19 bladder bladder cancer / / gene mutation 27091055
54 H19 thyroid thyroid cancer up onco miR-17-5p- YES1+ + - + + 27093644
55 H19 stomach gastric cancer up / 27184562
56 H19 bone osteosarcoma / / miR-141- 27186302
57 H19 ovary ovarian cancer up onco GSH metabolism chemotherapy resistance 27193186
58 H19 nervous system glioma up / MDR,MRP,ABCG2, + chemotherapy resistance 27366087

Expression profile

adipose adrenal brain breast colon heart kidney leukocyte liver lung lymph node ovary prostate skeletal muscle testis thyroid tissue 0 100 200 300 400 500 600 fpkm 244.0 47.0 0.3 223.0 90.0 68.0 49.0 0.0 31.0 25.0 63.0 137.0 139.0 581.0 181.0 501.0 H19

Expression profile in human body map

TCGA-BLCA TCGA-BRCA TCGA-CESC TCGA-HNSC TCGA-KICH TCGA-KIRC TCGA-KIRP TCGA-LIHC TCGA-LUAD TCGA-LUSC TCGA-PRAD TCGA-STAD TCGA-THCA TCGA-UCEC tissue 0 50 100 150 200 250 300 350 fpkm H19 type normal tumor

Expression profile in TCGA


Genomic feature visualization


Sequence

External link



Literature

[1]. Li C, Lei B, Huang S, Zheng M, Liu Z, et al. (2015). H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma. Am J Transl Res 7(10): 1747-64. link pubmed
[2]. Liu L, Yang J, Zhu X, Li D, Lv Z, et al. (2016). Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. FEBS J 283(12): 2326-39. link pubmed
[3]. Li X, Lin Y, Yang X, Wu X, He X (2016). Long noncoding RNA H19 regulates EZH2 expression by interacting with miR-630 and promotes cell invasion in nasopharyngeal carcinoma. Biochem Biophys Res Commun 473(4): 913-9. link pubmed
[4]. Zhang E, Li W, Yin D, De W, Zhu L, et al. (2016). c-Myc-regulated long non-coding RNA H19 indicates a poor prognosis and affects cell proliferation in non-small-cell lung cancer. Tumour Biol 37(3): 4007-15. link pubmed
[5]. Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, et al. (2015). H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget 6(30): 29209-23. link pubmed
[6]. Huang C, Cao L, Qiu L, Dai X, Ma L, et al. (2015). Upregulation of H19 promotes invasion and induces epithelial-to-mesenchymal transition in esophageal cancer. Oncol Lett 10(1): 291-296. link pubmed
[7]. Li H, Yu B, Li J, Su L, Yan M, et al. (2014). Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 5(8): 2318-29. link pubmed
[8]. Wang SH, Wu XC, Zhang MD, Weng MZ, Zhou D, et al. (2016). Upregulation of H19 indicates a poor prognosis in gallbladder carcinoma and promotes epithelial-mesenchymal transition. Am J Cancer Res 6(1): 15-26. link pubmed
[9]. Ma C, Nong K, Zhu H, Wang W, Huang X, et al. (2014). H19 promotes pancreatic cancer metastasis by derepressing let-7's suppression on its target HMGA2-mediated EMT. Tumour Biol 35(9): 9163-9. link pubmed
[10]. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, et al. (2010). Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 31(3): 350-8. link pubmed
[11]. Luo M, Li Z, Wang W, Zeng Y, Liu Z, et al. (2013). Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett 333(2): 213-21. link pubmed
[12]. Wang L, Cai Y, Zhao X, Jia X, Zhang J, et al. (2015). Down-regulated long non-coding RNA H19 inhibits carcinogenesis of renal cell carcinoma. Neoplasma 62(3): 412-8. link pubmed
[13]. Medrzycki M, Zhang Y, Zhang W, Cao K, Pan C, et al. (2014). Histone h1.3 suppresses h19 noncoding RNA expression and cell growth of ovarian cancer cells. Cancer Res 74(22): 6463-73. link pubmed
[14]. Zeira E, Abramovitch R, Meir K, Even Ram S, Gil Y, et al. (2015). The knockdown of H19lncRNA reveals its regulatory role in pluripotency and tumorigenesis of human embryonic carcinoma cells. Oncotarget 6(33): 34691-703. link pubmed
[15]. Zhang L, Yang F, Yuan JH, Yuan SX, Zhou WP, et al. (2013). Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis 34(3): 577-86. link pubmed
[16]. Lv J, Yu YQ, Li SQ, Luo L, Wang Q (2014). Aflatoxin B1 promotes cell growth and invasion in hepatocellular carcinoma HepG2 cells through H19 and E2F1. Asian Pac J Cancer Prev 15(6): 2565-70. link pubmed
[17]. Li S, Yu Z, Chen SS, Li F, Lei CY, et al. (2015). The YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long noncoding RNA. Urol Oncol 33(10): 427.e1-10. link pubmed
[18]. Hashad D, Elbanna A, Ibrahim A, Khedr G (2016). Evaluation of the Role of Circulating Long Non-Coding RNA H19 as a Promising Novel Biomarker in Plasma of Patients with Gastric Cancer. J Clin Lab Anal 30(6): 1100-1105. link pubmed
[19]. Luo M, Li Z, Wang W, Zeng Y, Liu Z, et al. (2013). Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. FEBS J 280(7): 1709-16. link pubmed
[20]. Zhou X, Ye F, Yin C, Zhuang Y, Yue G, et al. (2015). The Interaction Between MiR-141 and lncRNA-H19 in Regulating Cell Proliferation and Migration in Gastric Cancer. Cell Physiol Biochem 36(4): 1440-52. link pubmed
[21]. Han D, Gao X, Wang M, Qiao Y, Xu Y, et al. (2016). Long noncoding RNA H19 indicates a poor prognosis of colorectal cancer and promotes tumor growth by recruiting and binding to eIF4A3. Oncotarget 7(16): 22159-73. link pubmed
[22]. Cui J, Mo J, Luo M, Yu Q, Zhou S, et al. (2015). c-Myc-activated long non-coding RNA H19 downregulates miR-107 and promotes cell cycle progression of non-small cell lung cancer. Int J Clin Exp Pathol 8(10): 12400-9. link pubmed
[23]. He P, Zhang Z, Huang G, Wang H, Xu D, et al. (2016). miR-141 modulates osteoblastic cell proliferation by regulating the target gene of lncRNA H19 and lncRNA H19-derived miR-675. Am J Transl Res 8(4): 1780-8. link pubmed
[24]. Zhu Z, Song L, He J, Sun Y, Liu X, et al. (2015). Ectopic expressed long non-coding RNA H19 contributes to malignant cell behavior of ovarian cancer. Int J Clin Exp Pathol 8(9): 10082-91. link pubmed
[25]. Guo G, Kang Q, Chen Q, Chen Z, Wang J, et al. (2014). High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene. FEBS Lett 588(9): 1780-6. link pubmed
[26]. Jiang P, Wang P, Sun X, Yuan Z, Zhan R, et al. (2016). Knockdown of long noncoding RNA H19 sensitizes human glioma cells to temozolomide therapy. Onco Targets Ther 9: 3501-9. link pubmed
[27]. Sun H, Wang G, Peng Y, Zeng Y, Zhu QN, et al. (2015). H19 lncRNA mediates 17β-estradiol-induced cell proliferation in MCF-7 breast cancer cells. Oncol Rep 33(6): 3045-52. link pubmed
[28]. Xia Z, Yan R, Duan F, Song C, Wang P, et al. (2016). Genetic Polymorphisms in Long Noncoding RNA H19 Are Associated With Susceptibility to Breast Cancer in Chinese Population. Medicine (Baltimore) 95(7): e2771. link pubmed
[29]. Li S, Hua Y, Jin J, Wang H, Du M, et al. (2016). Association of genetic variants in lncRNA H19 with risk of colorectal cancer in a Chinese population. Oncotarget 7(18): 25470-7. link pubmed



© Bioinformatics Group of XTBG